Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/12/2003CA2468827A1 Insulin resistance improving agents
06/12/2003CA2468745A1 Induction of apoptosis in cancer cells
06/12/2003CA2468701A1 T-bet compositions and methods of use thereof
06/12/2003CA2468698A1 Methods and compositions for modulating the immune system and uses thereof
06/12/2003CA2468676A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
06/12/2003CA2468672A1 Antimicrobial composition comprising soy oil, rice bran oil and jojoba oil
06/12/2003CA2468556A1 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
06/12/2003CA2468539A1 Delivery of medicaments to the nail
06/12/2003CA2468525A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
06/12/2003CA2468471A1 Resorbable polymer composition, implant and method of making implant
06/12/2003CA2468463A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
06/12/2003CA2468349A1 Pyrimidine compounds
06/12/2003CA2468342A1 Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
06/12/2003CA2468067A1 Metabotropic glutamate receptor-5 modulators
06/12/2003CA2468044A1 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
06/12/2003CA2468040A1 Preparation of cis-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives
06/12/2003CA2467435A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003CA2467333A1 Methods for monitoring amyotrophic lateral sclerosis
06/12/2003CA2467073A1 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003CA2466762A1 Raf-mek-erk pathway inhibitors to treat cancer
06/12/2003CA2466757A1 Method for treating ocular hypertension
06/12/2003CA2466751A1 Ep4 receptor agonist, compositions and methods thereof
06/12/2003CA2466697A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/12/2003CA2466649A1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
06/12/2003CA2466570A1 Aminoacetonitrile derivatives and their use for controlling parasites
06/12/2003CA2466413A1 Flavivirus ns1 subunit vaccine
06/12/2003CA2465597A1 Amorphous and crystalline forms of losartan potassium and process for their preparation
06/12/2003CA2465395A1 Transdermal therapeutic systems containing steroid hormones and containing propylene glycol monocaprylate
06/12/2003CA2463794A1 Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
06/12/2003CA2462909A1 Methods for the treatment of hyperpigmentation of skin
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1318147A1 Novel pyrimidine derivative and novel pyridine derivative
06/11/2003EP1317929A2 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection
06/11/2003EP1317928A1 Wild apple polyphenol and process for producing the same
06/11/2003EP1317926A1 Xenon inhalant for pain treatment
06/11/2003EP1317925A1 Microgranules of Ursodeoxycholic acid
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317923A2 Compositions for increasing the survival of aquatic animals exposed to a RNA virus
06/11/2003EP1317922A1 Antipyretic preparation containing xylitol
06/11/2003EP1317921A1 Gel or solution containing dihydrotestosterone, its manufacture and use
06/11/2003EP1317915A1 Hair nourishments and method of screening the same
06/11/2003EP1317669A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
06/11/2003EP1317536A2 Tnf receptor-like molecules and uses thereof
06/11/2003EP1317533A1 Lubricated granules
06/11/2003EP1317489A1 A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy
06/11/2003EP1317486A1 Interferon-alpha induced gene
06/11/2003EP1317485A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317477A2 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers
06/11/2003EP1317470A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317459A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
06/11/2003EP1317458A2 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2alpha antagonists
06/11/2003EP1317457A2 INTERHETEROARYL 7-OXABICYCLIC 2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F 2$g(a)? ANTAGONISTS
06/11/2003EP1317456A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317446A1 Oxindole derivatives
06/11/2003EP1317445A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317442A1 Quinolinone derivatives as tyrosine kinase inhibitors
06/11/2003EP1317433A2 Inhibitors of glycogen synthase kinase 3
06/11/2003EP1317432A1 Piperidine derivatives for use as 2,3-oxidosqualene-lanosterol cyclase inhibitors
06/11/2003EP1317431A2 Polyarylcarboxamides useful as lipid lowering agents
06/11/2003EP1317430A1 (2-azabicyclo 2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
06/11/2003EP1317429A1 Amidine inhibitors of serine proteases
06/11/2003EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors
06/11/2003EP1317426A1 Beta-thio-amino acids
06/11/2003EP1317425A2 Resorcinol derivatives
06/11/2003EP1317424A2 Polyamine analogues as therapeutic and diagnostic agents
06/11/2003EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317419A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
06/11/2003EP1317418A2 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317416A2 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317413A1 Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
06/11/2003EP1317412A1 Compounds and compositions for delivering active agents
06/11/2003EP1317309A2 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
06/11/2003EP1317306A2 Transdermal electrotransport device and method for manufacturing same
06/11/2003EP1317304A1 Slow release pharmaceutical preparation and method of administering same
06/11/2003EP1317288A2 Method and composition for treating tumors by selective induction of apoptosis
06/11/2003EP1317287A2 Polymeric conjugates of antitumor agents
06/11/2003EP1317286A2 Contraception process and administration form for the same
06/11/2003EP1317284A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
06/11/2003EP1317272A2 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant
06/11/2003EP1317271A2 Therapeutic and cosmetic uses of heparanases
06/11/2003EP1317270A1 Exemestane for the treatment of oestrogen-dependent cancers
06/11/2003EP1317269A2 Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma
06/11/2003EP1317267A2 Compositions containing diacyltartaric salts of (e)-metanicotine
06/11/2003EP1317266A2 Neuroprotective 2-pyridinamine compositions and related methods
06/11/2003EP1317265A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
06/11/2003EP1317264A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders
06/11/2003EP1317263A1 Use of rhein for preparing a medicine for preventing articular cartilage damage
1 ... 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 5458 5459 5460 ... 7860